Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Update

Oragenics, Inc. (NYSEAMERICAN:OGEN) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 57,838 shares, a decrease of 46.5% from the December 31st total of 108,196 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 34,528 shares, the short-interest ratio is currently 1.7 days. Based on an average daily trading volume, of 34,528 shares, the short-interest ratio is currently 1.7 days. Currently, 1.5% of the company’s stock are short sold.

Oragenics Trading Up 2.4%

Shares of OGEN stock traded up $0.02 during mid-day trading on Friday, reaching $0.84. The stock had a trading volume of 59,373 shares, compared to its average volume of 913,663. The firm has a market cap of $3.59 million, a price-to-earnings ratio of -0.07 and a beta of 0.90. The business’s fifty day moving average is $0.87 and its 200-day moving average is $1.11. Oragenics has a 1-year low of $0.74 and a 1-year high of $18.90.

Oragenics (NYSEAMERICAN:OGEN) last released its quarterly earnings results on Friday, November 7th. The company reported ($1.96) earnings per share for the quarter.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of OGEN. Sabby Management LLC purchased a new stake in Oragenics in the 3rd quarter valued at $77,000. Bank of America Corp DE boosted its holdings in shares of Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares during the last quarter. Finally, Clear Street LLC acquired a new position in shares of Oragenics in the 2nd quarter valued at $270,000. Institutional investors and hedge funds own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.